Literature DB >> 29379162

PAX8 activates a p53-p21-dependent pro-proliferative effect in high grade serous ovarian carcinoma.

Dima Ghannam-Shahbari1, Eyal Jacob1, Reli Rachel Kakun1, Tanya Wasserman1, Lina Korsensky1, Ofir Sternfeld1, Juliana Kagan2, Debora Rosa Bublik3, Sarit Aviel-Ronen4, Keren Levanon5, Edmond Sabo6, Sarit Larisch2, Moshe Oren3, Dov Hershkovitz7, Ruth Perets8.   

Abstract

High grade serous carcinoma (HGSC) is the most common subtype of ovarian cancer and it is now widely accepted that this disease often originates from the fallopian tube epithelium. PAX8 is a fallopian tube lineage marker with an essential role in embryonal female genital tract development. In the adult fallopian tube, PAX8 is expressed in the fallopian tube secretory epithelial cell (FTSEC) and its expression is maintained through the process of FTSEC transformation to HGSC. We now report that PAX8 has a pro-proliferative and anti-apoptotic role in HGSC. The tumor suppressor gene TP53 is mutated in close to 100% of HGSC; in the majority of cases, these are missense mutations that endow the mutant p53 protein with potential gain of function (GOF) oncogenic activities. We show that PAX8 positively regulates the expression of TP53 in HGSC and the pro-proliferative role of PAX8 is mediated by the GOF activity of mutant p53. Surprisingly, mutant p53 transcriptionally activates the expression of p21, which localizes to the cytoplasm of HGSC cells where it plays a non-canonical, pro-proliferative role. Together, our findings illustrate how TP53 mutations in HGSC subvert a normal regulatory pathway into a driver of tumor progression.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29379162     DOI: 10.1038/s41388-017-0040-z

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  59 in total

Review 1.  Getting your Pax straight: Pax proteins in development and disease.

Authors:  Neil Chi; Jonathan A Epstein
Journal:  Trends Genet       Date:  2002-01       Impact factor: 11.639

2.  High-throughput chromatin immunoprecipitation for genome-wide mapping of in vivo protein-DNA interactions and epigenomic states.

Authors:  Ronnie Blecher-Gonen; Zohar Barnett-Itzhaki; Diego Jaitin; Daniela Amann-Zalcenstein; David Lara-Astiaso; Ido Amit
Journal:  Nat Protoc       Date:  2013-02-21       Impact factor: 13.491

3.  Male congenital hypothyroid Pax8-/- mice are infertile despite adequate treatment with thyroid hormone.

Authors:  Joachim Wistuba; Jens Mittag; C Marc Luetjens; Trevor G Cooper; Ching-Hei Yeung; Eberhard Nieschlag; Karl Bauer
Journal:  J Endocrinol       Date:  2007-01       Impact factor: 4.286

4.  Emerging roles for PAX8 in ovarian cancer and endosalpingeal development.

Authors:  Nathan J Bowen; Sanjay Logani; Erin B Dickerson; Laura B Kapa; Mariam Akhtar; Benedict B Benigno; John F McDonald
Journal:  Gynecol Oncol       Date:  2006-10-24       Impact factor: 5.482

5.  Cytoplasmic p21Cip1 is involved in Ras-induced inhibition of the ROCK/LIMK/cofilin pathway.

Authors:  Sungwoo Lee; David M Helfman
Journal:  J Biol Chem       Date:  2003-10-14       Impact factor: 5.157

6.  Specific loss of apoptotic but not cell-cycle arrest function in a human tumor derived p53 mutant.

Authors:  S Rowan; R L Ludwig; Y Haupt; S Bates; X Lu; M Oren; K H Vousden
Journal:  EMBO J       Date:  1996-02-15       Impact factor: 11.598

7.  Genome-wide analysis of androgen receptor targets reveals COUP-TF1 as a novel player in human prostate cancer.

Authors:  Ruth Perets; Tommy Kaplan; Ilan Stein; Guy Hidas; Shay Tayeb; Eti Avraham; Yinon Ben-Neriah; Itamar Simon; Eli Pikarsky
Journal:  PLoS One       Date:  2012-10-04       Impact factor: 3.240

8.  Enrichment of putative PAX8 target genes at serous epithelial ovarian cancer susceptibility loci.

Authors:  Siddhartha P Kar; Emily Adler; Jonathan Tyrer; Dennis Hazelett; Hoda Anton-Culver; Elisa V Bandera; Matthias W Beckmann; Andrew Berchuck; Natalia Bogdanova; Louise Brinton; Ralf Butzow; Ian Campbell; Karen Carty; Jenny Chang-Claude; Linda S Cook; Daniel W Cramer; Julie M Cunningham; Agnieszka Dansonka-Mieszkowska; Jennifer Anne Doherty; Thilo Dörk; Matthias Dürst; Diana Eccles; Peter A Fasching; James Flanagan; Aleksandra Gentry-Maharaj; Rosalind Glasspool; Ellen L Goode; Marc T Goodman; Jacek Gronwald; Florian Heitz; Michelle A T Hildebrandt; Estrid Høgdall; Claus K Høgdall; David G Huntsman; Allan Jensen; Beth Y Karlan; Linda E Kelemen; Lambertus A Kiemeney; Susanne K Kjaer; Jolanta Kupryjanczyk; Diether Lambrechts; Douglas A Levine; Qiyuan Li; Jolanta Lissowska; Karen H Lu; Jan Lubiński; Leon F A G Massuger; Valerie McGuire; Iain McNeish; Usha Menon; Francesmary Modugno; Alvaro N Monteiro; Kirsten B Moysich; Roberta B Ness; Heli Nevanlinna; James Paul; Celeste L Pearce; Tanja Pejovic; Jennifer B Permuth; Catherine Phelan; Malcolm C Pike; Elizabeth M Poole; Susan J Ramus; Harvey A Risch; Mary Anne Rossing; Helga B Salvesen; Joellen M Schildkraut; Thomas A Sellers; Mark Sherman; Nadeem Siddiqui; Weiva Sieh; Honglin Song; Melissa Southey; Kathryn L Terry; Shelley S Tworoger; Christine Walsh; Nicolas Wentzensen; Alice S Whittemore; Anna H Wu; Hannah Yang; Wei Zheng; Argyrios Ziogas; Matthew L Freedman; Simon A Gayther; Paul D P Pharoah; Kate Lawrenson
Journal:  Br J Cancer       Date:  2017-01-19       Impact factor: 7.640

9.  PAX2 expression in low malignant potential ovarian tumors and low-grade ovarian serous carcinomas.

Authors:  Celestine S Tung; Samuel C Mok; Yvonne T M Tsang; Zhifei Zu; Huijuan Song; Jinsong Liu; Michael T Deavers; Anais Malpica; Judith K Wolf; Karen H Lu; David M Gershenson; Kwong-Kwok Wong
Journal:  Mod Pathol       Date:  2009-06-12       Impact factor: 7.842

Review 10.  The consequence of oncomorphic TP53 mutations in ovarian cancer.

Authors:  Pavla Brachova; Kristina W Thiel; Kimberly K Leslie
Journal:  Int J Mol Sci       Date:  2013-09-23       Impact factor: 5.923

View more
  18 in total

Review 1.  PAX8 in the Junction between Development and Tumorigenesis.

Authors:  Reli Rachel Kakun; Zohar Melamed; Ruth Perets
Journal:  Int J Mol Sci       Date:  2022-07-03       Impact factor: 6.208

2.  SOX17 and PAX8 constitute an actionable lineage-survival transcriptional complex in ovarian cancer.

Authors:  Lifeng Lin; Kaixuan Shi; Shaoqing Zhou; Mei-Chun Cai; Caiyan Zhang; Yunheng Sun; Jingyu Zang; Lin Cheng; Kaiyan Ye; Pengfei Ma; Peiye Shen; Meiying Zhang; Yan Cheng; Chunting Qi; Ying Li; Xia Yin; Yiyan Zheng; Li Tan; Guanglei Zhuang; Rongyu Zang
Journal:  Oncogene       Date:  2022-02-05       Impact factor: 8.756

3.  The transcription factor PAX8 promotes angiogenesis in ovarian cancer through interaction with SOX17.

Authors:  Daniele Chaves-Moreira; Marilyn A Mitchell; Cristina Arruza; Priyanka Rawat; Simone Sidoli; Robbin Nameki; Jessica Reddy; Rosario I Corona; Lena K Afeyan; Isaac A Klein; Sisi Ma; Boris Winterhoff; Gottfried E Konecny; Benjamin A Garcia; Donita C Brady; Kate Lawrenson; Patrice J Morin; Ronny Drapkin
Journal:  Sci Signal       Date:  2022-04-05       Impact factor: 9.517

4.  Altered expression of long noncoding RNAs in peripheral blood mononuclear cells in patients with impaired leptomeningeal collaterals after acute anterior large vessel occlusions.

Authors:  Qisi Wu; Ting Li; Dan Zhu; Fajin Lv; Xinyue Qin
Journal:  Ann Transl Med       Date:  2019-10

Review 5.  Overview of PAX gene family: analysis of human tissue-specific variant expression and involvement in human disease.

Authors:  Brian Thompson; Emily A Davidson; Wei Liu; Daniel W Nebert; Elspeth A Bruford; Hongyu Zhao; Emmanouil T Dermitzakis; David C Thompson; Vasilis Vasiliou
Journal:  Hum Genet       Date:  2020-07-29       Impact factor: 4.132

6.  Before and After: Comparison of Legacy and Harmonized TCGA Genomic Data Commons' Data.

Authors:  Galen F Gao; Joel S Parker; Sheila M Reynolds; Tiago C Silva; Liang-Bo Wang; Wanding Zhou; Rehan Akbani; Matthew Bailey; Saianand Balu; Benjamin P Berman; Denise Brooks; Hu Chen; Andrew D Cherniack; John A Demchok; Li Ding; Ina Felau; Sharon Gaheen; Daniela S Gerhard; David I Heiman; Kyle M Hernandez; Katherine A Hoadley; Reyka Jayasinghe; Anab Kemal; Theo A Knijnenburg; Peter W Laird; Michael K A Mensah; Andrew J Mungall; A Gordon Robertson; Hui Shen; Roy Tarnuzzer; Zhining Wang; Matthew Wyczalkowski; Liming Yang; Jean C Zenklusen; Zhenyu Zhang; Han Liang; Michael S Noble
Journal:  Cell Syst       Date:  2019-07-24       Impact factor: 11.091

Review 7.  Unraveling the Mysteries of PAX8 in Reproductive Tract Cancers.

Authors:  Daniele Chaves-Moreira; Patrice J Morin; Ronny Drapkin
Journal:  Cancer Res       Date:  2020-12-23       Impact factor: 13.312

8.  The identification of nuclear αvβ3 integrin in ovarian cancer: non-paradigmal localization with cancer promoting actions.

Authors:  Chen Seraya-Bareket; Avivit Weisz; Elena Shinderman-Maman; Sharon Teper-Roth; Dina Stamler; Nissim Arbib; Yfat Kadan; Ami Fishman; Debora Kidron; Evgeny Edelstein; Martin Ellis; Osnat Ashur-Fabian
Journal:  Oncogenesis       Date:  2020-07-29       Impact factor: 7.485

9.  PAX8 plays an essential antiapoptotic role in uterine serous papillary cancer.

Authors:  Basem Fares; Liron Berger; Einav Bangiev-Girsh; Reli Rachel Kakun; Dima Ghannam-Shahbari; Yuval Tabach; Yaniv Zohar; Eyal Gottlieb; Ruth Perets
Journal:  Oncogene       Date:  2021-07-09       Impact factor: 9.867

Review 10.  FOXM1: A Multifunctional Oncoprotein and Emerging Therapeutic Target in Ovarian Cancer.

Authors:  Cassie Liu; Carter J Barger; Adam R Karpf
Journal:  Cancers (Basel)       Date:  2021-06-19       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.